Optimizing Research Documentation: Oncology Consultants & Flatiron
Oncology Consultants relied on paper-based research logs for clinical trials, which caused delayed investigator sign-offs and data-entry inconsistencies as staff rotated between locations. They switched to electronic adverse-event documentation within Flatiron's OncoEMR system. Median time to investigator sign-off dropped to 5 hours, down from 24-48 hours on paper, while monitor queries decreased and data quality improved; their Research Quality Assurance Manager is quoted saying the change "allows me to easily track adverse events that are unsigned by investigators, improving data quality."
Flatiron Health is a Roche-owned company supplying EHR-derived oncology real-world data, captured at the source through its own OncoEMR software.
This sits in the Data Providers stage of the AI use-case lifecycle: Named examples from the real-world-data, claims and competitive-intelligence providers pharma AI systems are trained on, benchmarked against, or run inside of.
Published by Flatiron Health on its own site — read the original case study on resources.flatiron.com ↗
Related use cases
- 01Novartis - Taf + Mek external control analysis (BRAF V600E NSCLC), from Flatiron Health's RWE case studies (ResearchX Episode 5)
- 02Amgen - Lumakras/KRAS G12C natural history study, from Flatiron Health's RWE case studies (ResearchX Episode 5)
- 03Takeda - mobocertinib/Exkivity benchmark analysis, from Flatiron Health's RWE case studies (ResearchX Episode 5)
- 04A retrospective electronic health record-derived study supporting the accelerated approval of a new drug for mantle cell lymphoma in the U.S.
- 05Real-world clinical outcomes and comparative effectiveness of a drug in patients with recurrent ovarian cancer in the U.S.
- 06Kadcyla (T-DM1) in HER2+ mBC: Label Update on LVEF following a post approval commitment - based on RWD